Rising teen obesity prompts a surge in Novo Nordisk's Wegovy usage among adolescents, with prescriptions climbing 50% in 2024 ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Hims agreed to buy private European telehealth firm Zava, which operates in the U.K., Germany, France, and Ireland.

Hims did not provide financial terms of the deal, but a company spokesperson said these details will be shared with its ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

Stocks are struggling at the start of trade as lingering trade worries stick to this market, though investors managed to shake that off on Monday. That setup could work again for Tuesday. The S&P 500 ...

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

The data shows that the average rate of adolescents starting treatment with the Novo Nordisk (NYSE: NVO) drug increased by 50 ...